Cytovance Biologics Revenue and Competitors
Estimated Revenue & Valuation
- Cytovance Biologics's estimated annual revenue is currently $65.3M per year.
- Cytovance Biologics's estimated revenue per employee is $217,000
- Cytovance Biologics's total funding is $42.5M.
Employee Data
- Cytovance Biologics has 301 Employees.
- Cytovance Biologics grew their employee count by -3% last year.
Cytovance Biologics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Commercial Officer (CCO) | Reveal Email/Phone |
2 | CEO | Reveal Email/Phone |
3 | Chief Operating Officer | Reveal Email/Phone |
4 | VP Program Management | Reveal Email/Phone |
5 | Executive Director, Quality Control | Reveal Email/Phone |
6 | Associate Director Microbial Bioprocess | Reveal Email/Phone |
7 | Associate Director Quality Assurance | Reveal Email/Phone |
8 | Associate Director Manufacturing (Upstream / Fill Finish) | Reveal Email/Phone |
9 | Sr Director Research & Development | Reveal Email/Phone |
10 | Senior Director Quality | Reveal Email/Phone |
Cytovance Biologics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $0.9M | 6 | 0% | N/A | N/A |
#2 | $0.8M | 5 | 0% | N/A | N/A |
#3 | $17.4M | 112 | 3% | N/A | N/A |
#4 | $0.8M | 5 | 0% | N/A | N/A |
#5 | $65.3M | 301 | -3% | $42.5M | N/A |
#6 | $7.9M | 51 | 4% | N/A | N/A |
#7 | $2.8M | 18 | 0% | N/A | N/A |
#8 | $3.6M | 46 | -6% | $14M | N/A |
#9 | $1.4M | 9 | 0% | N/A | N/A |
#10 | $0.9M | 6 | 0% | N/A | N/A |
What Is Cytovance Biologics?
Our mission is to be the definitive full service contract manufacturer for the production of clinical scale therapeutic proteins and antibodies for the biotech industry. The Cytovance team understands from first-hand experience the need for more options for comprehensive contract manufacturing services. While there is some debate about the size of the cell culture capacity shortage for commercial stage biopharmaceutical products, the adequacy of clinical capacity is an equally critical question, especially for development stage companies. The clinical manufacturing capacity that does exist is mostly controlled by larger therapeutics companies or commercial scale contractors that are often inaccessible to development stage clients.
keywords:N/A
$42.5M
Total Funding
301
Number of Employees
$65.3M
Revenue (est)
-3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cytovance Biologics News
Merck; SGS; WuXi AppTec; Thermo Fisher Scientific; Sartorius; Cytovance Biologics; Pace Analytical Services; Toxikon. Analysis of Cardan Shaft...
... Inc., Merck KGaA, Lonza Group Ltd., SGS S.A., Thermo Fisher Scientific Inc., Wuxi Apptec, Sartorius AG, Cytovance Biologics, Inc.
McCool himself has 15 years of experience in the CDMO industry, having had technical and leadership roles at Lonza and Cytovance Biologics.
Together, the Cytovance upstream and downstream platform processes meet a key need in the biologic industry to produce high quality product in conjunction with accelerated timelines and reduced costs on the path from cell line to clinical material. TORONTO (PRWEB) August 23, 2021 Despite the w ...
Cytovance Biologics, Inc., Oklahoma City, Oklahoma-based contract manufacturing organization of mammalian and microbial biologics, received a $20m senior credit facility. Monroe Capital provided the financing. The company intends to use the funds to continue to grow operations. Cytovance work ...
Other Companies in Oklahoma City
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $15M | 306 | 1% | N/A |
#2 | $15M | 309 | 7% | N/A |
#3 | $85M | 309 | N/A | N/A |
#4 | $94.9M | 310 | N/A | N/A |
#5 | N/A | 311 | 14% | N/A |